5 results on '"Junking, Mutita"'
Search Results
2. Chimeric Antigen Receptor T Cells Targeting Integrin αvβ6 Expressed on Cholangiocarcinoma Cells.
- Author
-
Phanthaphol, Nattaporn, Somboonpatarakun, Chalermchai, Suwanchiwasiri, Kwanpirom, Chieochansin, Thaweesak, Sujjitjoon, Jatuporn, Wongkham, Sopit, Maher, John, Junking, Mutita, and Yenchitsomanus, Pa-thai
- Subjects
CHIMERIC antigen receptors ,T cell receptors ,INTEGRINS ,CHOLANGIOCARCINOMA ,T cells ,FOOT & mouth disease - Abstract
Cholangiocarcinoma (CCA) is a lethal bile duct cancer that responds poorly to current standard treatments. A new therapeutic approach is, therefore, urgently needed. Adoptive T cell transfer using chimeric antigen receptor (CAR) T cells is a new therapeutic modality with demonstrated efficacy in hematologic malignancies. However, its efficacy against solid tumors is modest, and further intensive investigation continues. An important factor that influences the success of CAR T cell therapy is the selection of a target antigen that is highly expressed on cancer cells, but markedly less so in normal cells. Integrin αvβ6 is upregulated in several solid tumors, but is minimally expressed in normal epithelial cells, which suggests integrin αvβ6 as an attractive target antigen for CAR T cell immunotherapy in CCA. We investigated integrin αvβ6 expression in pathological tissue samples from patients with liver fluke-associated CCA. We then created CAR T cells targeting integrin αvβ6 and evaluated their anti-tumor activities against CCA cells. We found overexpression of the integrin αvβ6 protein in 23 of 30 (73.3%) CCA patient tissue samples. Significant association between high integrin αvβ6 expression and short survival time (p = 0.043) was also observed. Lentiviral constructs were engineered to encode CARs containing an integrin αvβ6-binding peptide (A20) derived from foot-and-mouth disease virus fused with a second-generation CD28/CD3ζ signaling domain (A20-2G CAR) or with a fourth-generation CD28/4-1BB/CD27/CD3ζ signaling domain (A20-4G CAR). The A20-2G and A20-4G CARs were highly expressed in primary human T cells transduced with the engineered lentiviruses, and they exhibited high levels of cytotoxicity against integrin αvβ6-positive CCA cells (p < 0.05). Interestingly, the A20-2G and A20-4G CAR T cells displayed anti-tumor function against integrin αvβ6-positive CCA tumor spheroids (p < 0.05). Upon specific antigen recognition, A20-4G CAR T cells produced a slightly lower level of IFN-γ, but exhibited higher proliferation than A20-2G CAR T cells. Thus, the A20-4G CAR T cells with lower level of cytokine production, but with higher proliferation represents a promising potential adoptive T cell therapy for integrin αvβ6-positive CCA. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. Precision immunotherapy for cholangiocarcinoma: Pioneering the use of human-derived anti-cMET single chain variable fragment in anti-cMET chimeric antigen receptor (CAR) NK cells.
- Author
-
Chiawpanit, Chutipa, Wathikthinnakorn, Methi, Sawasdee, Nunghathai, Phanthaphol, Nattaporn, Sujjitjoon, Jatuporn, Junking, Mutita, Yamabhai, Montarop, Panaampon, Jutatip, Yenchitsomanus, Pa-thai, and Panya, Aussara
- Subjects
- *
CHIMERIC antigen receptors , *KILLER cells , *CHOLANGIOCARCINOMA , *TRANSMEMBRANE domains , *IMMUNOTHERAPY , *CELL culture - Abstract
[Display omitted] • The expression of cMET was predominantly observed in cholangiocarcinoma (CCA) cell lines which supported the cMET as a target for CCA. • In this study, we screened and characterized novel single chain variable fragment (ScFv) targeted cMET and generated an anti-cMET CAR-NK cells to treat CCA. • The anti-cMET CAR-NK cells exhibited specificity and favorable cytotoxicity against high-cMET CCA cell line in in vitro model. Cholangiocarcinoma (CCA) presents a significant clinical challenge which is often identified in advanced stages, therby restricting the effectiveness of surgical interventions for most patients. The high incidence of cancer recurrence and resistance to chemotherapy further contribute to a bleak prognosis and low survival rates. To address this pressing need for effective therapeutic strategies, our study focuses on the development of an innovative cellular immunotherapy, specifically utilizing chimeric antigen receptor (CAR)-engineered natural killer (NK) cells designed to target the cMET receptor tyrosine kinase. In this investigation, we initiated the screening of a phage library displaying human single-chain variable fragment (ScFv) to identify novel ScFv molecules with specificity for cMET. Remarkably, ScFv11, ScFv72, and ScFv114 demonstrated exceptional binding affinity, confirmed by molecular docking analysis. These selected ScFvs, in addition to the well-established anti-cMET ScFvA, were integrated into a CAR cassette harboring CD28 transmembrane region-41BB-CD3ζ domains. The resulting anti-cMET CAR constructs were transduced into NK-92 cells, generating potent anti-cMET CAR-NK-92 cells. To assess the specificity and efficacy of these engineered cells, we employed KKU213A cells with high cMET expression and KKU055 cells with low cMET levels. Notably, co-culture of anti-cMET CAR-NK-92 cells with KKU213A cells resulted in significantly increased cell death, whereas no such effect was observed with KKU055 cells. In summary, our study identified cMET as a promising therapeutic target for CCA. The NK-92 cells, armed with the anti-cMET CAR molecule, have shown strong ability to kill cancer cells specifically, indicating their potential as a promising treatment for CCA in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition.
- Author
-
Yuti, Pornpimon, Wutti-in, Yupanun, Sawasdee, Nunghathai, Kongkhla, Katesara, Phanthaphol, Nattaporn, Choomee, Kornkan, Chieochansin, Thaweesak, Panya, Aussara, Junking, Mutita, Yenchitsomanus, Pa-thai, and Sujjitjoon, Jatuporn
- Subjects
- *
PROGRAMMED death-ligand 1 , *CHIMERIC antigen receptors , *B cells , *MONOCLONAL antibodies , *T cell receptors , *PROGRAMMED cell death 1 receptors , *T cells , *B cell lymphoma , *CELL receptors - Abstract
[Display omitted] • Anti-CD19-CAR5-T cells exerted more effective cytotoxicity than anti-CD19-CAR4-T cells at a low effector-to-target ratio. • Cytotoxicity of anti-CD19-CAR4-T cells was inhibited by upregulations of PD-1 on CAR-T cells and PD-L1 on the target cancer cells. • The secreted anti-PD-L1 scFv from anti-CD19-CAR5-T cells could restore the cytotoxic effect of anti-CD19-CAR4-T cells. • The secreted anti-PD-L1 scFv promoted self-proliferation of anti-CD19-CAR5-T cells. • PD-L1 blockade by anti-PD-L1 scFv secreted from CAR5-T cells is a feasible strategy to improve CAR-T antitumor efficiency. Adoptive T cell therapy using second-generation anti-CD19 chimeric antigen receptor T cells (anti-CD19-CAR2-T) induced complete remission in many heavily pretreated patients with B cell acute lymphoblastic leukemia (B-ALL) or diffuse large B cell lymphoma (DLBCL). However, poor clinical efficacy was observed in treating aggressive B cell lymphomas (BCL). The limited T cell function was reported by programmed cell death protein 1 ligand (PD-L1) expressed on BCL cells bound to the PD-1 receptor on T cells. To overcome this problem, we generated anti-CD19-CAR4-T cells secreting anti-PD-L1 single-chain variable fragment (scFv), namely anti-CD19-CAR5-T cells, and evaluated their functions in vitro. Both anti-CD19-CAR-T cells contain an anti-CD19 scFv derived from a monoclonal antibody, FMC63, linked to CD28/4-1BB/CD27/CD3ζ. The secreting anti-PD-L1 scFv is derived from atezolizumab. Our results showed that secreted anti-PD-L1 scFv could bind to PD-L1 and block the binding of anti-PD-L1 monoclonal antibodies on PD-L1high tumor cells. Anti-CD19-CAR4-T and anti-CD19-CAR5-T cells efficiently killed CD19+ target tumor cells in two-dimensional (2D) and three-dimensional (3D) co-culture systems. However, anti-CD19-CAR5-T cells demonstrated superior proliferative ability. Interestingly, at a low effector (E) to target (T) ratio of 0.5:1, anti-CD19-CAR5-T cells showed higher cytotoxicity against CD19+/PD-L1high cells compared to that of anti-CD19-CAR4-T cells. The cytotoxicity of anti-CD19-CAR4-T cells against CD19+/PD-L1high could be restored by adding anti-PD-L1 scFv. Our findings demonstrate the combination antitumor efficiency of anti-CD19-CAR4-T cells and anti-PD-L1 scFv against CD19+/PD-L1high tumors. As such, anti-CD19-CAR5-T cells should be further investigated in vivo antitumor efficiency and clinical trials as a treatment for aggressive B cell lymphoma. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells.
- Author
-
Sangsuwannukul, Thanich, Supimon, Kamonlapat, Sujjitjoon, Jatuporn, Phanthaphol, Nattaporn, Chieochansin, Thaweesak, Poungvarin, Naravat, Wongkham, Sopit, Junking, Mutita, and Yenchitsomanus, Pa-thai
- Subjects
- *
CHIMERIC antigen receptors , *CD19 antigen , *LYSIS , *CHOLANGIOCARCINOMA , *CANCER stem cells ,BILIARY tract cancer - Abstract
• CD133 expression in patient tissues and cholangiocarcinoma (CCA) cells were shown. • Anti-CD133 CAR4 T cells containing CD28/CD137/CD27/CD3ς was successfully created. • The concept of using anti-CD133 CAR4 T cells against CD133+ CCA cells is proved. • Anti-CD133 CAR4 T cells is a potential cancer immunotherapy for CCA treatment. Current treatment of cholangiocarcinoma (CCA) – a lethal bile duct cancer – is ineffective because the disease is usually diagnosed at late and advanced stage. Thus, a novel therapeutic modality is urgently required. Fourth-generation chimeric antigen receptor (CAR4) T cells was created to target CD133, a well-known cancer stem cell marker, that is highly expressed and associates with cancer progression. The anti-CD133-CAR4 T cells showed high efficacy against CD133-expressing CCA cells. Tumour cell lysis occurred in a dose- and CD133 antigen-dependent manner, and significantly higher, up to 57.59% ± 9.62 at effector to target ratio of 5:1 in a CCA cell line – KKU-213A cells, compared to mock control (p = 0.008). Similarly, significant IFN-γ (p = 0.011) and TNF-α (p = 0.002) upregulation was observed upon tumour treatment. The effectiveness of our anti-CD133-CAR4 T cells will be beneficial not only for CD133-expressing CCA, but also for other CD133-expressing tumours. This study may guide future in vivo study and clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.